Literature DB >> 26846109

Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma.

Weidong Shi1, Wei Huang2, Yuyan Chen3, Shusen Zhang2, Pan Xu4, Xiaoling Gu4, Hui Fan1, Jian Xu1, Yongmei Chen1, Runzhou Ni2, Cuihua Lu5, Xiubing Zhang6.   

Abstract

p53-induced death domain protein (PIDD) facilitates p53-dependent apoptosis through the interaction with components of the death receptor signaling pathways. However, the role of PIDD in hepatocellular carcinoma (HCC) development remains unknown. In this study, we investigated the expression pattern of PIDD in clinical HCC samples and adjacent non-cancerous tissues using immunohistochemistrical and Western blot analyses. The results showed that PIDD was lowly expressed in HCC tissues and HCC cell lines, compared with the adjacent non-tumorous tissues and LO2 normal hepatocytes. In addition, clinicopathological analysis showed that the expression of PIDD was closely related with multiple clinicopathological variables, such as American Joint Committee on Cancer (AJCC) stage, AFP, and poor prognosis of HCC. Univariate and multivariate survival analyses demonstrated that PIDD could serve as an independent prognostic factor to predict the survival of HCC patients. We used serum starvation-refeeding experiment to explore the involvement of PIDD in HCC cell cycle regulation. We found that PIDD was accumulated in growth-arrested HCC cells and was progressively decreased when cells entered into S phase. Moreover, flow cytometry and cell counting kit-8 (CCK-8) assays indicated that depleting the expression of PIDD could facilitate cell cycle progression and accelerate cell proliferation in HepG2 cells, while overexpression of PIDD could result in cell cycle arrest at G1 phase and hinder the cell proliferation in Hep3B cells. Finally, flow cytometry revealed that overexpression of PIDD slightly increased the apoptosis of HCC cells. Taken together, we concluded that PIDD may be a valuable prognostic marker and promising therapeutic target of HCC.

Entities:  

Keywords:  Apoptosis; Hepatocellular carcinoma; PIDD; Proliferation

Mesh:

Substances:

Year:  2016        PMID: 26846109     DOI: 10.1007/s13277-015-4556-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress.

Authors:  Antoine Tinel; Jürg Tschopp
Journal:  Science       Date:  2004-04-08       Impact factor: 47.728

3.  PIDD mediates NF-kappaB activation in response to DNA damage.

Authors:  Sophie Janssens; Antoine Tinel; Saskia Lippens; Jürg Tschopp
Journal:  Cell       Date:  2005-12-16       Impact factor: 41.582

4.  MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.

Authors:  C Wan; S Hou; R Ni; L Lv; Z Ding; X Huang; Q Hang; S He; Y Wang; C Cheng; X X Gu; G Xu; A Shen
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

5.  p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury.

Authors:  Rohit Seth; Cheng Yang; Varsha Kaushal; Sudhir V Shah; Gur P Kaushal
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

6.  The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development.

Authors:  Jinyu Ren; Mingan Shi; Renshui Liu; Qi-Heng Yang; Teri Johnson; William C Skarnes; Chunying Du
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-07       Impact factor: 11.205

Review 7.  A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses.

Authors:  Vandana Moudgil; Davender Redhu; Suman Dhanda; Jasbir Singh
Journal:  J Environ Pathol Toxicol Oncol       Date:  2013       Impact factor: 3.567

Review 8.  Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?

Authors:  Richard S Finn
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 9.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

10.  Toward an understanding of the protein interaction network of the human liver.

Authors:  Jian Wang; Keke Huo; Lixin Ma; Liujun Tang; Dong Li; Xiaobi Huang; Yanzhi Yuan; Chunhua Li; Wei Wang; Wei Guan; Hui Chen; Chaozhi Jin; Juncheng Wei; Wanqiao Zhang; Yongsheng Yang; Qiongming Liu; Ying Zhou; Cuili Zhang; Zhihao Wu; Wangxiang Xu; Ying Zhang; Tao Liu; Donghui Yu; Yaping Zhang; Liang Chen; Dewu Zhu; Xing Zhong; Lixin Kang; Xiang Gan; Xiaolan Yu; Qi Ma; Jing Yan; Li Zhou; Zhongyang Liu; Yunping Zhu; Tao Zhou; Fuchu He; Xiaoming Yang
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

View more
  2 in total

1.  Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.

Authors:  Yuepeng Jin; Qiang Li; Junjun Qiu; Xiufen Zhao; Chunxiao Zheng; Shixu Lv; Yongyu Bai; Yunfeng Shan; Le-Chi Ye
Journal:  Tumour Biol       Date:  2016-08-23

2.  Response to Different Oxygen Partial Pressures and Evolution Analysis of Apoptosis-Related Genes in Plateau Zokor (Myospalax baileyi).

Authors:  Zhifang An; Xiaoqi Chen; Jimei Li
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.